244 related articles for article (PubMed ID: 11960320)
1. The proteasome: a novel target for cancer chemotherapy.
Almond JB; Cohen GM
Leukemia; 2002 Apr; 16(4):433-43. PubMed ID: 11960320
[TBL] [Abstract][Full Text] [Related]
2. Conformational change and mitochondrial translocation of Bax accompany proteasome inhibitor-induced apoptosis of chronic lymphocytic leukemic cells.
Dewson G; Snowden RT; Almond JB; Dyer MJ; Cohen GM
Oncogene; 2003 May; 22(17):2643-54. PubMed ID: 12730678
[TBL] [Abstract][Full Text] [Related]
3. p27Kip1 accumulation by inhibition of proteasome function induces apoptosis in oral squamous cell carcinoma cells.
Kudo Y; Takata T; Ogawa I; Kaneda T; Sato S; Takekoshi T; Zhao M; Miyauchi M; Nikai H
Clin Cancer Res; 2000 Mar; 6(3):916-23. PubMed ID: 10741716
[TBL] [Abstract][Full Text] [Related]
4. The proteasome inhibitor bortezomib promotes mitochondrial injury and apoptosis induced by the small molecule Bcl-2 inhibitor HA14-1 in multiple myeloma cells.
Pei XY; Dai Y; Grant S
Leukemia; 2003 Oct; 17(10):2036-45. PubMed ID: 14513055
[TBL] [Abstract][Full Text] [Related]
5. Genistein-induced apoptosis of p815 mastocytoma cells is mediated by Bax and augmented by a proteasome inhibitor, lactacystin.
Park BS; Baek SJ; Song KH; Kim KH; Jeong SJ; Jeong MH; Seo SY; Lee SW; Yoo KS; Yoo YH
Nutr Cancer; 2002; 42(2):248-55. PubMed ID: 12416267
[TBL] [Abstract][Full Text] [Related]
6. Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem.
Landis-Piwowar KR
Clin Lab Sci; 2012; 25(1):38-44. PubMed ID: 22458048
[TBL] [Abstract][Full Text] [Related]
7. Combined proteasome and Bcl-2 inhibition stimulates apoptosis and inhibits growth in EBV-transformed lymphocytes: a potential therapeutic approach to EBV-associated lymphoproliferative diseases.
Srimatkandada P; Loomis R; Carbone R; Srimatkandada S; Lacy J
Eur J Haematol; 2008 May; 80(5):407-18. PubMed ID: 18221384
[TBL] [Abstract][Full Text] [Related]
8. Lactacystin, a proteasome inhibitor, potentiates the apoptotic effect of parthenolide, an inhibitor of NFkappaB activation, on drug-resistant mouse leukemia L1210 cells.
Cory AH; Cory JG
Anticancer Res; 2002; 22(6C):3805-9. PubMed ID: 12552998
[TBL] [Abstract][Full Text] [Related]
9. Regulation of apoptosis proteins in cancer cells by ubiquitin.
Zhang HG; Wang J; Yang X; Hsu HC; Mountz JD
Oncogene; 2004 Mar; 23(11):2009-15. PubMed ID: 15021888
[TBL] [Abstract][Full Text] [Related]
10. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) alpha, and TNF-related apoptosis-inducing ligand in prostate cancer.
An J; Sun YP; Adams J; Fisher M; Belldegrun A; Rettig MB
Clin Cancer Res; 2003 Oct; 9(12):4537-45. PubMed ID: 14555528
[TBL] [Abstract][Full Text] [Related]
11. Targeting proteasome inhibition in hematologic malignancies.
Hideshima T; Richardson PG; Anderson KC
Rev Clin Exp Hematol; 2003 Jun; 7(2):191-204. PubMed ID: 14763162
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effect of the human immunodeficiency virus protease inhibitor ritonavir: induction of tumor-cell apoptosis associated with perturbation of proteasomal proteolysis.
Gaedicke S; Firat-Geier E; Constantiniu O; Lucchiari-Hartz M; Freudenberg M; Galanos C; Niedermann G
Cancer Res; 2002 Dec; 62(23):6901-8. PubMed ID: 12460905
[TBL] [Abstract][Full Text] [Related]
13. JNK and AP-1 mediate apoptosis induced by bortezomib in HepG2 cells via FasL/caspase-8 and mitochondria-dependent pathways.
Lauricella M; Emanuele S; D'Anneo A; Calvaruso G; Vassallo B; Carlisi D; Portanova P; Vento R; Tesoriere G
Apoptosis; 2006 Apr; 11(4):607-25. PubMed ID: 16528474
[TBL] [Abstract][Full Text] [Related]
14. Interferon-gamma-induced sensitization of colon carcinomas to ZD9331 targets caspases, downstream of Fas, independent of mitochondrial signaling and the inhibitor of apoptosis survivin.
Geller J; Petak I; Szucs KS; Nagy K; Tillman DM; Houghton JA
Clin Cancer Res; 2003 Dec; 9(17):6504-15. PubMed ID: 14695155
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.
Ling YH; Liebes L; Jiang JD; Holland JF; Elliott PJ; Adams J; Muggia FM; Perez-Soler R
Clin Cancer Res; 2003 Mar; 9(3):1145-54. PubMed ID: 12631620
[TBL] [Abstract][Full Text] [Related]
16. Effects of the proteasome inhibitor, bortezomib, on apoptosis in isolated lymphocytes obtained from patients with chronic lymphocytic leukemia.
Pahler JC; Ruiz S; Niemer I; Calvert LR; Andreeff M; Keating M; Faderl S; McConkey DJ
Clin Cancer Res; 2003 Oct; 9(12):4570-7. PubMed ID: 14555532
[TBL] [Abstract][Full Text] [Related]
17. Regulation of CD95 (Fas/APO-1)-induced apoptosis in human chondrocytes.
Kühn K; Lotz M
Arthritis Rheum; 2001 Jul; 44(7):1644-53. PubMed ID: 11465715
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibitor, bortezomib, potently inhibits the growth of adult T-cell leukemia cells both in vivo and in vitro.
Satou Y; Nosaka K; Koya Y; Yasunaga JI; Toyokuni S; Matsuoka M
Leukemia; 2004 Aug; 18(8):1357-63. PubMed ID: 15190257
[TBL] [Abstract][Full Text] [Related]
19. Tannic acid potently inhibits tumor cell proteasome activity, increases p27 and Bax expression, and induces G1 arrest and apoptosis.
Nam S; Smith DM; Dou QP
Cancer Epidemiol Biomarkers Prev; 2001 Oct; 10(10):1083-8. PubMed ID: 11588135
[TBL] [Abstract][Full Text] [Related]
20. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors.
Pei XY; Dai Y; Grant S
Clin Cancer Res; 2004 Jun; 10(11):3839-52. PubMed ID: 15173093
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
